MicroRNA profiling and the role of microRNA-132 in neurodegeneration using a rat model

Neuroscience Letters

Volumn 553, Issue , 2013, Pages 153-158

  Lungu, Gina ^a   Stoica, George ^a   Ambrus, Andy ^a  

^a TEXAS A AND M UNIVERSITY   (United States)

Author keywords

BDNF; MicroRNA; MicroRNA 132; Neurodegeneration; Nurr1; Rat model

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; MICRORNA 132; MICRORNA 20A; MICRORNA 29A; MICRORNA 29B; NUCLEAR RECEPTOR RELATED FACTOR 1; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); TRANSCRIPTION FACTOR E2F;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DOUBLE STRANDED DNA BREAK; DOWN REGULATION; G1 PHASE CELL CYCLE CHECKPOINT; IMMUNOHISTOCHEMISTRY; MESENCEPHALON; MICROARRAY ANALYSIS; MITOCHONDRIAL MEMBRANE POTENTIAL; NERVE CELL DIFFERENTIATION; NERVE DEGENERATION; NERVOUS SYSTEM DEVELOPMENT; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RNA INTERFERENCE; WESTERN BLOTTING;

BDNF; MICRORNA; MICRORNA-132; NEURODEGENERATION; NURR1; RAT MODEL;

ANIMALS; BRAIN-DERIVED NEUROTROPHIC FACTOR; DISEASE MODELS, ANIMAL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; MESENCEPHALON; MICRORNAS; NERVE DEGENERATION; NUCLEAR RECEPTOR SUBFAMILY 4, GROUP A, MEMBER 2; RATS;

EID: 84884382763     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2013.08.001     Document Type: Article

References (40)

1. Bargaje R., Gupta S., Sarkeshik A., Park R., Xu T., Sarkar M., Halimani M., Roy S.S., Yates J., Pillai B. Identification of novel targets for miR-29a using miRNA proteomics. PLoS ONE 2012, 7:e43243.
2. Bolstad B.M., Irizarry R.A., Astrandand M., Speed T.P. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinfo 2003, 19:185-193.
3. Brett J.O., Renault V.M., Rafalski V.A., Webb A.E., Brunet A. The microRNA cluster miR-106-25 regulates adult neural stem/progenitor cell proliferation and neuronal differentiation. Aging 2011, 3:2.
4. Brodersen P., Voinnet O. Revisting the principles of microRNA target recognition and mode of action. Nat. Rev Mol. Cell Biol 2009, 10:141-148.
5. Chu Y., Le W., Kompoliti K., Jankovic J., Mufson J.E., Kordower J.H. Nurr1 in Parkinson's disease and related disorders. The Journal of Comparative Neurology 2006, 494:495-514.
6. Cloonan N., Brown K.M., Steptoe A.L., Wani S., Chan W.L., Forrest A.R.R., Kolle Z.G., Gabrielli B., Grimmond S.M. The miR-17-5p microRNA is a key regulator of the G1/S phase cell cycle transition. Genome Biology 2008, 9:R127.
7. Decressac M., Kadkhodaei B., Mattsson B., Laguna A., Perlmann T., Bjorklund A. α-Synuclein-induced down-regulation of Nurr1 disrupts GDNF signaling in nigral dopamine neurons. Parkinson's Disease 2012, 4:163.
8. De Rijk M.C., Launer L.J., Berger K., Breteler M.M., Dartigues J.F., Baldereschi M., Fratiglioni L., Lobo A., Martinez-Lage J., Renkwalder C. Prevalence of Parkinson's disease in Europe: a collaborative study of population-based cohorts. Neurology 2005, 54:S21-S23.
9. Eisen M.B., Spellman P.T., Brown P.O., Botstein D. Cluster analysis and display of genome-wide expression patterns. Proceedings of the National Academy of Sciences of the United States of America 1998, 95:14863-14868.
10. Fang J., Song X.W., Tian J., Chen H.Y., Li D.F., Wang J.F., Ren A.J., Yuan W.J., Lin L. Overexpression of microRNA-378 attenuates ischemia-induced apoptosis by inhibiting caspase-3 expression in cardiac myocytes. Apoptosis 2012, 17:410-423.
11. Foshay M.K., Gallicano G.I. miR-17 family miRNAs are expressed during early mammalian development and regulate stem cell differentiation. Developmental Biology 2001, 326:431-443.
12. Gao X., Gulari E., Zhou X. In situ synthesis of oligonucleotide microarrays. Biopolymers 2004, 73:579-596.
13. Gao F.B. Posttranscriptional control of neuronal development by miRNA networks. Trends in Neurosciences 2008, 31:20-26.
14. Gascon E., Gao F.B. Cause or effect: misregulation of microRNA pathways in neurodegeneration. Frontiers in Neuroscience 2012, 6:48.
15. Harraz M.M., Dawson T.M., Dawson V.L. MicroRNAs in Parkinson's disease. Journal of Chemical Neuroanatomy 2011, 42:127-130.
16. Hoglinger G.U., Breuning J.J., Depboylu C., Rouaux C., Michel P.P., Alvarez-Fisher D., Boutillier A.L., DeGregori J., Oertel W.H., Rakic P., Hirsch E.C., Hunot S. The Rb/E2F cell-cycle pathway mediates cell death in Parkinson's disease. Proceedings of the National Academy of Sciences of the United States of America 2007, 104:3585-3590.
17. Howells D.W., Porritt M.J., Wong J.Y., Batchelor P.E., Kalnins R., Hughes A.J., Donnan G.A. Reduced BDNF mRNA expression in the Parkinson's disease substantia nigra. Experimental Neurology 2000, 166:127-135.
18. Jiand C., Wan X., He Y., Pan T., Jankovic J., Le W. Age dependent dopaminergic dysfunction in Nurr1 knockout mice. Experimental Neurology 2005, 191:154-162.
19. Junn E., Mouradian M.M. MicroRNAs in neurodegenerative diseases and their therapeutic potential. Pharmacology and Therapeutics 2012, 133:142-150.
20. Luo G.R., Chen Y., Li X.P., Li X.T., Le W.D. Nr4a2 is essential for differentiation of dopaminergic neurons during zebrafish embryogenesis. Molecular and Cell Neuroscience 2008, 39:202-210.
21. Kim H.T., Qiang W., Wong P.K., Stoica G. Enhanced proteolysis of Ikappaβalpha and IkappaBbeta proteins in astrocytes by Moloney murine leukemia virus (MoMuLV)-ts1 infection: a potential mechanism of NF-kappaB activation. Journal of Neurovirology 2001, 7:466-475.
22. Lungu G., Stoica G., Wong P.K.Y. Down-regulation of Jab1, HIF-1α, and VEGF by Molony Murine Leukemia Virus-ts1 infection: a possible cause of neurodegeneration. Journal of Neurovirology 2008, 1:239-325.
23. Miller B.H., Zeier Z., Lanz T.A., Xi L., Deng S., Strathmann J., Willoughby D., Kenny P.J., Elsworth J.D., Lawrence M.S., Roth R.H., Edbauer D., Kleiman R.J., Wahlestedt C. MicroRNA-132 dysregulation in schizophrenia has implication for both neurodevelopment and adult brain function. Proceedings of the National Academy of Sciences of the United States of America 2011, 6:45-51.
24. Mogi M., Togari A., Kondo T., Mizuno Y., Komure O., Kuno S., Ichinose H., Nagatsu T. Brain-derived growth factor and nerve growth factor concentrations are decreased in the substantia nigra in Parkinson's disease. Neuroscience Letters 1999, 270:45-48.
25. Mott J.L., Kobayashi S., Bronk S.F., Gores G.J. mir-29 regulates Mcl-1 protein expression and apoptosis. Oncogene 2007, 42:6133-6140.
26. Pan W. A comparative review of statistical methods for discovering differentially expressed genes in replicated microarray experiments. Bioinformatics 2002, 18:546-554.
27. Pickering M.T., Stadler B.M., Kowalik T.F. miR-17 and miR-20a temper an E2F-induced G1 checkpoint to regulate cell cycle progression. Oncogene 2009, 28:140-145.
28. Sacchetti P., Mitchell T.R., Granneman J.G., Bannon M.J. Nurr1 enhances transcription of human dopamine transporter gene through a novel mechanisms. Journal of Neurochemistry 2001, 7:1565-1572.
29. Sakurada K., Ohshima-Sakurada M., Palmer T.D., Gage F.H. Nurr1 an orphan nuclear receptor is a transcriptional activator of endogenous tyrosine hydroxylase in neural progenitor cells derived from the adult brain. Development 1999, 126:4017-4026.
30. Scalzo P., Kummer A., Bretas T.L., Cardoso F., Teixeira A.L. Serum levels of brain-derived neurotrophic factor correlate with motor impairment in Parkinson's disease. Journal of Neurology 2010, 257:540-545.
31. Shi G., Liu Y., Liu T., Yan W., Liu X., Wang Y., Shi J., Jia L. Upregulated miR-29b promotes neuronal cell death by inhibiting Bcl2L2 after ischemic brain injury. Experimental Brain Research 2002, 216:225-230.
32. Soreq H., Wolf Y. NeurimmiRs: microRNAs in the neuroimmune interface. Trends in Molecular Medicine 2011, 17:548-555.
33. Stoica G., Lungu G., Bjorklund N.L., Taglialatela G., Zhang X., Chiu V., Hill H.H., Schenk J.O., Murray I. Potential role of α-synuclein in neurodegeneration: studies in a rat animal model. Journal of Neurochemistry 2002, 122:812-822.
34. Ventura A., Young A.G., Winslow M.M., Lintault L., Meissner A., Erkeland S.J. Targeted deletion reveals essential and overlapping functions of the miR-17 through 92 family of miRNA clusters. Cell 2008, 132:875-886.
35. Volpicelli F., Caiazzo M., Greco D., Consales C., Leone L., Perrone-Capano C., D'Amato L.C., Di Porzio U. Bdnf gene is a downstream target of Nurr1 transcription factor in rat midbrain neurons in vitro. Journal of Neurochemistry 2007, 102:441-453.
36. Wanet A., Tacheny A., Arnould T., Renard P. miR212/132 expression and function: within and beyond the neuronal compartment. Nucleic Acids Research 2012, 1:12.
37. Weidon L., Chen S., Jankovic J. Etiopathogenesis of Parkinson disease: a new beginning?. Neuroscientist 2009, 15:28-35.
38. Xiong Y., Fang J.H., Yun J.P., Yang J., Zhang Y., Jia W.H., Zhuang S.M. Effects of microRNA-29 on apoptosis, tumorigenicity, and prognosis of hepatocellular carcinoma. Hepatology 2010, 51:836-845.
39. Yang D., Li T., Tang Y., Cui H., Tang Y., Zhang X., Chen D., Shen N., Le W. miR-132 regulates the differentiated of dopamine neurons by directly targeting Nurr1 expression. Journal of Cell Science 2012, 125:1673-1682.
40. Yuan Y., Sun J., Zhao M., Hu J., Wang X., Du G., Chen N.H. Overexpression of α-synuclein down-regulates BDNF expression. Cellular and Molecular Neurobiology 2010, 30:939-946.